To compare the efficacy and safety of silodosin and dutasteride combination with alfuzosin and dutasteride combination in patients of benign prostatic hyperplasia: a randomized, open label study

Simple item page
dc.contributor.authorKahkashan, Iramen_US
dc.contributor.authorChawdhary, Shabnamen_US
dc.contributor.authorTandon, Vishal R.en_US
dc.contributor.authorGupta, Rahulen_US
dc.date.accessioned2020-04-23T07:55:15Z
dc.date.available2020-04-23T07:55:15Z
dc.date.issued2019-04
dc.description.abstractBackground: BPH is a major cause of bothersome lower urinary tract symptoms (LUTS) and affects quality of life (QoL) which deteriorates if not taken care with the passage of time. The aim and objective of the study was to compare the efficacy and safety of combination of silodosin and dutasteride with the combination of alfuzosin and dutasteride in patients of BPH.Methods: A randomized, open label, intention to treat study was carried out on newly diagnosed patients of BPH. Patients were randomly divided into two groups and followed up to 12 weeks. Group 1 of patients received a combination of silodosin 8 mg and dutasteride 0.5 mg (SD) (n=20) while the patients of group 2 received combination of alfuzosin 10 mg and dutasteride 0.5 mg (AD) (n=20). Primary endpoint was measured by changes in the mean baseline International prostate symptom score (I-PSS) and uroflowmetry and secondary outcome with changes observed on ultrasonography.Results: IPSS and IPSS-QOL significantly improved in both the treatment groups (p <0.001) along with mean maximum flow rate (Qmax) and mean average flow rate (Qavg). Prostate volume and residual urine volume showed a significant improvement in both the treatment groups at 12 weeks. However, the intergroup differences in IPSS, uroflowmetry and USG parameters were not significant. Both treatments were well tolerated.Conclusions: The current study established that both the drug combinations i.e. silodosin and dutasteride (SD) and alfuzosin and dutasteride (AD) largely have a comparable effect on both the dynamic and static components of BPH. Further, both drug combinations appear to have a comparable safety profile.en_US
dc.identifier.affiliationsDepartment of Pharmacology, SKIMS Medical College and Hospital, Bemina, Srinagar, Jammu and Kashmir, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacology, GMC Jammu, Jammu and Kashmir, Indiaen_US
dc.identifier.affiliationsDepartment of Urology, Govt. Superspeciality Hospital, Jammu, Jammu and Kashmir, Indiaen_US
dc.identifier.citationKahkashan Iram, Chawdhary Shabnam, Tandon Vishal R., Gupta Rahul. To compare the efficacy and safety of silodosin and dutasteride combination with alfuzosin and dutasteride combination in patients of benign prostatic hyperplasia: a randomized, open label study. International Journal of Basic & Clinical Pharmacology. 2019 Apr; 8(4): 635-641en_US
dc.identifier.issn2319-2003
dc.identifier.issn2279-0780
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/200115
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber4en_US
dc.relation.volume8en_US
dc.source.urihttps://dx.doi.org/10.18203/2319-2003.ijbcp20191095en_US
dc.subjectAlfuzosinen_US
dc.subjectBPHen_US
dc.subjectDutasterideen_US
dc.subjectSilodosinen_US
dc.titleTo compare the efficacy and safety of silodosin and dutasteride combination with alfuzosin and dutasteride combination in patients of benign prostatic hyperplasia: a randomized, open label studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijbcp2019v8n4p635.pdf
Size:
365.88 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Basic & Clinical Pharmacology